Melanotan II (MT-2)
Melanotan II is a lab-made ring-shaped copy of alpha-MSH, the natural hormone that controls skin colour, first developed at the University of Arizona in the 1980s and 1990s. It has been studied in small human trials of tanning and erectile dysfunction, and in animal research.
At a glance
- Peptide
- Not yet audited here; the reference library calls it emerging
- 500 mcg per Peptide Dosing Protocols. All 2 sources
- 10 mg in 2 mL
How much to draw
Full calculator →Opened on 500 mcg, the figure Peptide Dosing Protocols reports for Melanotan II (MT-2), and a 10 mg vial in 2 mL. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Melanotan II (MT-2) or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Loading: 0.25-0.5 mg daily; Maintenance: 0.5-1.0 mg 1-2 times per week | Daily during loading (1-3 weeks); 1-2 times per week for maintenanceLoading: 2-4 weeks; Maintenance: ongoing as desired | subcutaneous or oral | Peptide Protocol Wiki |
| Standard: 500-1000 mcg daily · Low: 100-250 mcg daily · High: 250-500 mcg daily | 1-2x per week4-6 weeks · 6 weeks | Subcutaneous (SubQ) injection | Peptide Dosing ProtocolsWhat it saysHideHalf-life: half-life Melanotan 2 ~1-2 hours Afamelanotide(MT-I) ~0. The standard loading dose is 500-1000 mcg daily. |
- Daily during loading (1-3 weeks); 1-2 times per week for maintenanceLoading: 2-4 weeks; Maintenance: ongoing as desired
- subcutaneous or oral
- Peptide Protocol Wiki
- 1-2x per week4-6 weeks · 6 weeks
- Subcutaneous (SubQ) injection
- Peptide Dosing Protocols
What it saysHide
Half-life: half-life Melanotan 2 ~1-2 hours Afamelanotide(MT-I) ~0. The standard loading dose is 500-1000 mcg daily.
- Bacteriostatic water
- 2 mL BAC water
We have not published an audit on Melanotan II (MT-2). Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Melanotan II copies a natural hormone that tells the body to make skin pigment, but it is stronger and lasts longer, which is why its effects and its side effects are both bigger. Researchers link this to melanocortin receptors, a family that sits on different cells and controls pigment, hunger and sexual signalling, and most modern drugs target only one of them while MT-2 hits several at once. Visible tanning usually needs brief UV exposure as well as dosing, and lighter skin types tend to change sooner than darker ones. The published human evidence is small and old, mostly trials of 20 to 100 people from the 1990s and early 2000s, and MT-2 itself was never submitted for FDA approval.
Melanotan 2 works by turning on a family of receptors in your body called melanocortin receptors. These receptors sit on different cells and control different things: skin pigment, hunger, sexual signaling, and more. Most modern drugs are designed to hit only one receptor. MT-2 hits several at once. [Source: Peptide Dosing Protocols]
Reported side effects
Seen in studies: a Phase I study in healthy volunteers found clear pigmentation gains alongside frequent nausea and spontaneous erections at the doses studied. Phase II trials in erectile dysfunction reported strong erection responses and higher sexual desire compared with placebo, again with notable nausea rates.
Reported by users: nausea and flushing, a warm red feeling in the face and chest, are the most common and usually ease over the first week or two. Many also report eating less, feeling sleepy or yawning soon after a dose.
Not ruled out: MT-2 can darken existing moles and freckles and trigger new ones, and case reports describe new moles and rapid changes to old ones after only one or two doses, which matters because mole changes can signal melanoma, a serious skin cancer. A few case reports describe priapism, a painful lasting erection treated as a medical emergency. Overdose case reports at levels far above typical research ranges describe rhabdomyolysis, muscle breakdown that can damage the kidneys.
Who should avoid it
People with a personal or family history of melanoma: case reports have linked MT-2 use to mole changes and melanoma diagnoses.
People with many moles or atypical moles: MT-2 darkens existing moles and can trigger new ones, which makes a genuine warning sign easier to miss.
People with cardiovascular conditions: flushing, blood pressure changes and rare reports of more serious events point to higher risk with uncontrolled cardiovascular disease.
People with a history of priapism or sickle cell trait: case reports include priapism, a prolonged painful erection needing medical care.
People who are pregnant or breastfeeding: no human safety data exists for either group.
People taking medications that affect blood pressure or arousal: there is little drug-interaction data, and sources say blood pressure, erectile dysfunction and psychiatric medications are worth reviewing with a clinician first.
What gets monitored
Photograph moles before starting and every few weeks during use; monitor for any changes in shape, color, or size. (reported by Peptide Dosing Protocols)
Common questions
What starting dose do Melanotan 2 protocols describe?
Reported amounts and schedules for Melanotan II (MT-2) differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.
What is Melanotan 2's half-life?
The plasma half-life is about 1 to 2 hours. The lab-made version is stronger and longer-lasting than the natural alpha-MSH hormone it copies.
How fast do tanning results appear?
Most users report some pigment change in 1 to 2 weeks during the loading phase. Visible change usually requires brief UV exposure as well, and lighter skin types tend to see it sooner than darker ones.
How is Melanotan 2 reconstituted?
That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.
Is Melanotan 2 FDA-approved?
No. As of June 2026 MT-2 is not approved by the FDA and was never submitted for approval. More selective successors were developed instead: afamelanotide for pigmentation, approved for a rare skin condition, and bremelanotide (PT-141) for sexual function.
What are the most common Melanotan 2 side effects?
Nausea and flushing are the most common, and both tend to ease over the first week or two of dosing. Appetite changes, fatigue and yawning are also frequently reported.
Is Melanotan 2 linked to skin cancer?
Case reports have documented mole darkening and new moles after MT-2 use, sometimes after only one or two doses. Because mole changes can signal melanoma, sources describe photographing moles before and during use and seeing a dermatologist if a mole changes shape, colour or size or starts to bleed.
How does Melanotan 2 compare to PT-141?
MT-2 is non-selective, so it produces tanning, sexual and appetite effects together. PT-141, also called bremelanotide, is one of the more selective successors researchers built instead, and it is FDA-approved for low sexual desire in women.
Sources
- 01Dorr RT, Lines R, Levine N, et al. Evaluation of Melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences (1996)
- 02Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction. Journal of Urology (1998)
- 03Wessells H, Gralnek D, Dorr R, et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology (2000)
- 04Wessells H, Levine N, Hadley ME, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. International Journal of Impotence Research (2000)
- 05Dorr RT, Ertl GA, Levine N, et al. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Archives of Dermatology (2004)
- 06Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clinical Toxicology (2012)
- 07Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology (2014)
- 08Schulze F, Erdmann H, Hardkop LH, et al. Eruptive naevi and darkening of pre-existing naevi 24 h after a single mono-dose injection of melanotan II. European Journal of Dermatology (2014)
- 09Mallory CW, Lopategui DM, Cordon BH. Melanotan tanning injection: a rare cause of priapism. Sexual Medicine (2021)
- 10Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues. International Journal of Dermatology (2017)
- 11Minakova E, Lang J, Medel-Matus JS, et al. Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism. Translational Psychiatry (2019)
- 12Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides (2006)
- 13Wikipedia contributors. Melanotan II. Wikipedia, The Free Encyclopedia (2026)
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small lab-made molecule, not a true peptide, though it is often sold alongside research peptides. It is studied for shrinking fat cells and raising NAD+ levels, and all evidence so far comes from cell and rodent studies, with no published human trial.
BPC-157 (Body Protection Compound 157) is a lab-made chain of 15 amino acids based on a sequence first found in human gastric juice. It is mostly studied in animal models of tendon, ligament, gut and blood-vessel injury, and human evidence is limited to three small pilots.
Cerluten is an oral peptide bioregulator referenced for nervous system support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.
CJC-1295 with DAC is a lab-made 30-amino-acid copy of growth hormone-releasing hormone, altered so it attaches to albumin, a protein in the blood. It was studied in early human trials for its effect on growth hormone and IGF-1 levels.
This is a combination research blend sold as one vial: CJC-1295 without DAC, a copy of growth hormone-releasing hormone, plus Ipamorelin, a short peptide that acts on the ghrelin receptor. It is studied as a GHRH and GHRP pairing in growth-hormone research.
Endoluten is a peptide bioregulator taken by mouth, listed in the reference library as pineal support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.